Efficacy and Safety of MA and MAL on reducing body weight and body fat

Efficacy and Safety of MA and MAL on reducing body weight and body fat in overweight subjects; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004012

Enrollment

150

Registered

2019-05-30

Start date

2018-08-14

Completion date

Unknown

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : - Test group I (test food I): taken once a day, three times a day for 12weeks , once with plenty of water (1.69 g / day as MA extract) - Test group II (test food II): taken once a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Adults 20 years of age or older and 65 years of age or younger 2) Body mass index (BMI) is greater than 25, less than 32 3) The person who agrees to participate in this study and wrote the written informed consent

Exclusion criteria

Exclusion criteria: 1) Those with severe cerebrovascular disease, heart disease (angina pectoris, myocardial infarction, heart failure, or arrhythmia requiring treatment) within the past 6 months. 2) Those taking drugs affecting body weight within the past month (absorption inhibitors and appetite suppressants, health functional foods / supplements related to obesity improvement, psychiatric drugs such as depression, beta-blockers, diuretics, oral contraceptive pills, steroids and female hormones) 3) Unadjusted hypertension patients (blood pressure of 160/100 mmHg or higher) 4) Diabetic patients with fasting blood glucose levels greater than 126 mg / dl or with oral hypoglycemic agents or insulin 5) Thyroid stimulating hormone (TSH) less than 0.1 µU / ml or more than 10 µU / ml or currently taking thyroid hormone 6) Creatinine is at least twice the normal upper limit of the test facility 7) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is more than three times the normal upper limit. 8) Persons with severe gastrointestinal disturbances who are suffering from ingestion of test food 9) Those who were admitted to the hospital, or have received medication or rehabilitation due to alcohol use 10) Those who cannot exercise because of musculoskeletal disorders 11) Those who participated in the commercial obesity program within the last 3 months 12) Those who participated or planned to participate in other clinical trials within the past one month

Design outcomes

Primary

Measure	Time frame
Body fat percentage and fat mass through Dual-energy X-ray absorptiometry (DEXA)	—

Secondary

Measure	Time frame
Body weight;Waist circumference;Hip circumference;Body mass index;Blood lipid;C-Reactive Protein (CRP)	—

Countries

Korea, Republic of

Contacts

Public ContactHYEJIN CHUN

Bundang CHA General Hospital

fmewha@naver.com+82-31-780-5000

Outcome results